Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo
Over the past 5 years, a new generation of highly potent and broadly neutralizing HIV-1
antibodies has been identified. These antibodies can protect against lentiviral infection in …
antibodies has been identified. These antibodies can protect against lentiviral infection in …
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
Passive immunization with HIV-1–neutralizing monoclonal antibodies (mAbs) is being
considered for prevention and treatment of HIV-1 infection. As therapeutic agents, mAbs …
considered for prevention and treatment of HIV-1 infection. As therapeutic agents, mAbs …
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to …
KH Mayer, KE Seaton, Y Huang, N Grunenberg… - PLoS …, 2017 - journals.plos.org
Background VRC01 is an HIV-1 CD4 binding site broadly neutralizing antibody (bnAb) that
is active against a broad range of HIV-1 primary isolates in vitro and protects against simian …
is active against a broad range of HIV-1 primary isolates in vitro and protects against simian …
Broadly neutralizing antibodies in HIV-1 treatment and prevention
Antibodies that naturally develop in some individuals infected with human immunodeficiency
virus 1 (HIV-1) and are capable of broadly neutralizing diverse strains of HIV-1 are useful for …
virus 1 (HIV-1) and are capable of broadly neutralizing diverse strains of HIV-1 are useful for …
Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor
HIV-1 infection depends on effective viral entry mediated by the interaction of its envelope
(Env) glycoprotein with specific cell surface receptors. Protective antiviral antibodies …
(Env) glycoprotein with specific cell surface receptors. Protective antiviral antibodies …
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial
TA Crowell, DJ Colby, S Pinyakorn, C Sacdalan… - The lancet HIV, 2019 - thelancet.com
Background HIV-1-specific broadly neutralising antibodies such as VRC01 could promote
HIV remission by halting viral replication and clearing infected cells. We investigated …
HIV remission by halting viral replication and clearing infected cells. We investigated …
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial
MR Gaudinski, KV Houser, NA Doria-Rose… - The Lancet …, 2019 - thelancet.com
Background Human monoclonal antibodies that potently and broadly neutralise HIV-1 are
under development to prevent and treat HIV-1 infection. In this phase 1 clinical trial we …
under development to prevent and treat HIV-1 infection. In this phase 1 clinical trial we …
De novo identification of VRC01 class HIV-1–neutralizing antibodies by next-generation sequencing of B-cell transcripts
J Zhu, X Wu, B Zhang, K McKee… - Proceedings of the …, 2013 - National Acad Sciences
Next-generation sequencing of antibody transcripts provides a wealth of data, but the ability
to identify function-specific antibodies solely on the basis of sequence has remained elusive …
to identify function-specific antibodies solely on the basis of sequence has remained elusive …
HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies
Broadly neutralizing antibodies (bNAbs) have been isolated from selected HIV-1-infected
individuals and shown to bind to conserved sites on the envelope glycoprotein (Env) …
individuals and shown to bind to conserved sites on the envelope glycoprotein (Env) …
Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults
Clinical & Experimental Immunology, 2015 - academic.oup.com
Summary VRC-HIVMAB060-00-AB (VRC01) is a broadly neutralizing HIV-1 monoclonal
antibody (mAb) isolated from the B cells of an HIV-infected patient. It is directed against the …
antibody (mAb) isolated from the B cells of an HIV-infected patient. It is directed against the …